Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER IMMUNOTHERAPY

Arming T cells to infiltrate pancreatic tumours

Nature Biomedical Engineering volume 5, pages 1243–1245 (2021)Cite this article

Subjects

The efficacy of adoptive cell therapy for pancreatic cancer can be augmented by antigen-specific cytotoxic T cells genetically engineered to overexpress a C-X-C chemokine receptor whose ligand is highly expressed by pancreatic cancer cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Adoptively transferred T cells engineered to overexpress CXCR6 infiltrate and accumulate in the vasculature of pancreatic tumours.

References

  1. June, C. H. & Sadelain, M. N. Engl. J. Med. 379, 64–73 (2018).

    Article  CAS  Google Scholar 

  2. Grupp, S. A. et al. N. Engl. J. Med. 368, 1509–1518 (2013).

    Article  CAS  Google Scholar 

  3. Brentjens, R. J. et al. Sci. Transl. Med. 5, 177ra38 (2013).

    Article  Google Scholar 

  4. Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Cancer Cell 36, 471–482 (2019).

    Article  CAS  Google Scholar 

  5. Lesch, S. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-021-00737-6 (2021).

    Article  PubMed  Google Scholar 

  6. Davenport, A. J. et al. Cancer Immunol. Res. 3, 483–494 (2015).

    Article  CAS  Google Scholar 

  7. Morello, A., Sadelain, M. & Adusumilli, P. S. Cancer Discov. 6, 133–146 (2016).

    Article  CAS  Google Scholar 

  8. Beatty, G. L. et al. Gastroenterology 155, 29–32 (2018).

    Article  CAS  Google Scholar 

  9. Pastan, I. & Hassan, R. Cancer Res. 74, 2907–2912 (2014).

    Article  CAS  Google Scholar 

  10. Kachala, S. S. et al. Clin. Cancer Res. 20, 1020–1028 (2014); erratum 20, 3896 (2014).

  11. Servais, E. L. et al. Clin. Cancer Res. 18, 2478–2489 (2012).

    Article  CAS  Google Scholar 

  12. Cherkassky, L. et al. J. Clin. Invest. 126, 3130–3144 (2016).

    Article  Google Scholar 

  13. Adusumilli, P. S. et al. Sci. Transl. Med. 6, 261ra151 (2014).

    Article  Google Scholar 

  14. Adusumilli, P. S. et al. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-21-0407 (2021).

    Article  PubMed  Google Scholar 

  15. Brown, C. E. et al. N. Engl. J. Med. 375, 2561–2569 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

    Leonid Cherkassky

  2. Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

    Leonid Cherkassky

  3. Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Prasad S. Adusumilli

  4. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Prasad S. Adusumilli

Authors
  1. Leonid Cherkassky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prasad S. Adusumilli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prasad S. Adusumilli.

Ethics declarations

Competing interests

P.S.A. has received research funding from ATARA Biotherapeutics and Acea Biosciences; has served on the scientific advisory boards of, or as a consultant for, ATARA Biotherapeutics, Bayer, Carisma Therapeutics, Imugene, ImmpactBio and Takeda Therapeutics; has pending patent applications on T-cell therapies; and has patents, royalties and intellectual property on mesothelin-targeted CARs and other T-cell therapies and on methods for the detection of cancer cells using viruses. L.C. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cherkassky, L., Adusumilli, P.S. Arming T cells to infiltrate pancreatic tumours. Nat Biomed Eng 5, 1243–1245 (2021). https://doi.org/10.1038/s41551-021-00821-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41551-021-00821-x

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research